Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

<p>Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib. The prospective, observational REFINE study aimed to evaluate the safety and effectiveness...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Karger Publishers 2025-01-01
Colección:	Liver Cancer
Acceso en línea:	https://karger.com/article/doi/10.1159/000542285
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!